- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid TumorsCancer Discovery, 14(6), 1048–1063 (2024)
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic CancerClinical Colorectal Cancer, 23(3), 272-284 (2024)
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.Authors Derek Wong; Ping Luo; Leslie E. Oldfield; Haifan Gong; Ledia Brunga; Ron Rabinowicz; Vallijah Subasri; Clarissa Chan; Tiana Downs; Kirsten M. Farncombe; Beatrice Luu; Maia Norman; Julia A. Sobotka; Precious Uju; Jenna Eagles; Stephanie Pedersen; Johanna Wellum; Arnavaz Danesh; Stephenie D. Prokopec; Eric Y. Stutheit-Zhao; Nadia Znassi; Lawrence E. Heisler; Richard Jovelin; Bernard Lam;… Read more: Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionClinical Cancer Research, 29(18), 3706–3716 (2023)
- Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healingFrontiers in Endocrinology, 14, (2023)
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic CancerNature, 617, 147–153 (2023)
- Coronavirus disease 2019 (COVID-19) outbreak on an in-patient medical unit associated with unrecognized exposures in common areas—Epidemiological and whole-genome sequencing investigationInfection Control & Hospital Epidemiology, 44(11), 1829 – 1833 (2023)
- Integrated, Longitudinal Analysis of Cell-free DNA in Uveal MelanomaCancer Research Communications, 3(2), 267–280 (2023)
- A polygenic two-hit hypothesis for prostate cancerJournal of the National Cancer Institute, 115(4), 468–472 (2023)
- In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy ProgramHaematologica, 108(1), 196-206 (2023)
- hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 28(23), 5115–5120 (2022)
- Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in CanadaScientific Reports, 12, Article number: 10867 (2022)
- Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with Fusobacterium nucleatum and Its Subspecies animalisCancer Epidemiology, Biomarkers & Prevention, 31(1), 210–220 (2022)
- Early signatures of breast cancer up to seven years prior to clinical diagnosis in plasma cell-free DNA methylomesResearch Square, (2022)
- DNA Methylation-Based Classification of Small B-Cell Lymphomas: A Proof-of-Principle StudyThe Journal of Molecular Diagnostics, 23(12), 1774-1786 (2021)
- The telomere length landscape of prostate cancerNature Communications, 12, Article number: 6893 (2021)
- Pancreatic cancer evolution and heterogeneity: integrating omics and clinical dataNature Reviews Cancer, 22, 131–142 (2022)
- Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyJournal for ImmunoTherapy of Cancer, 9, (2021)
- Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literatureJournal of Clinical Pathology, 76, 158-165 (2023)
- Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityNature Communications, 12, Article number: 5137 (2021)
Publications
To learn more about our work and research, check out a curated list of our published articles!
